Arena Pharmaceuticals, Inc. (ARNA)

[jdolby32]

Bidwackie - notice he just said discussions about how to sell more product. No one will merge with them and distribute for them with the REMS. Doctors will not Rx this product because they can get generics for their patients cheaper. What a concept . . . you take two products already in generic form (available to the public) and combine them to get an FDA approval. And one of the products is banned in the EU. Really . . . how stupid does this make the FDA look? They only saved face by issuing a REMS designation. I don't have any evidence of course, but I still feel there are some very important people in high places caught up in the short hedge funds as clients. I believe favors were ask of the DEA to prolong the classification as well as not wave Eisai's 30 day request. However, time ran out as pressure was building on the DEA to 'explain' their prolonged response, so now it comes down to a 30 day scramble for the boys caught short on ARNA and long in VVUS to figure a way out. Biggest problem is that there are major long funds locked into ARNA (50% of OS) as well as a major contingent of super longs who bought in pre-$3 range who will not be scared out of their shares. So this becomes a conundrum as it's almost impossible to frighten either of these groups into selling. It is also costing them steep interest rates to control their short positions.

I truly believe the x-factor in Belviq's success will be the T2D application. The longer the EU postures with their non-clinical BS the more Belviq will become a major black market product. JMO